Clinical trials: Rivaroxaban
Stroke, Embolism
Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients
This is local prospective multicenter observational non-interventional local study. Primary study objective is investigate and describe prescription pattern of neurologists in secondary stroke or non-CNS (non-Central Nervous…
- Trial name
- NEURO-XAR (NCT01925755)
- Testing
- Rivaroxaban ( Xarelto, BAY59-7939)
- Where
- Russia
- Volunteers
- 209 people
- Sponsor
- Bayer
Diabetes
ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)
Diabetic and nondiabetic patients will be evaluated if they had a first diagnosis of non-valvular atrial fibrillation and in therapy with non-vitamin K oral anticoagulants and with vitamin K oral anticoagulants.
- Trial name
- ORGANON (NCT02935855)
- Testing
- Dabigatran, Apixaban, Rivaroxaban
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- University of Pavia
Atrial Fibrillation or Pulmonary Embolism, Need of Long Term Oral Anticoagulation Therapy (OAT)
Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification
The following trial hypothesis will be proved: In patients with atrial fibrillation and/ or pulmonary embolism standard anticoagulant treatment with coumadin/phenprocoumon is associated with accelerated coronary or valvular…
- Conditions
- Atrial Fibrillation or Pulmonary Embolism, Need of Long Term Oral Anticoagulation Therapy (OAT), Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location
- Trial name
- NCT02066662
- Testing
- Rivaroxaban or Marcumar
- Where
- 3 sites in Germany
- Volunteers
- 192 people
- Sponsor
- RWTH Aachen University
Uterine Hemorrhage, Cardiovascular Diseases
A Study on Abnormal Menstrual Bleeding in Chinese Women of Childbearing Age Taking Antithrombotic Drugs After Cardiovascular Surgery
This study aims to investigate uterine bleeding during menstruation in women taking antithrombotic medications after cardiac surgery.
- Conditions
- Uterine Hemorrhage, Cardiovascular Diseases, Antithrombotic Drugs
- Trial name
- NCT07870941
- Testing
- antithrombotic drugs
- Where
- China
- Volunteers
- 1,308 people
- Sponsor
- Shanghai Zhongshan Hospital
Combined Anticoagulation and Antithrombotic Therapy, PAD - Peripheral Arterial Disease
Effectiveness of Combined Anticoagulation and Antithrombotic Therapy vs Antithrombotic Therapy Alone After Lower Extremity Revascularization for Peripheral Arterial Disease
EFFECTIVENESS OF COMBINED ANTICOAGULATION AND ANTITHROMBOTIC THERAPY VS ANTITHROMBOTIC THERAPY ALONE AFTER LOWER EXTREMITY REVASCULARIZATION FOR PERIPHERAL ARTERIAL DISEASE.
- Trial name
- NCT04994223
- Testing
- Rivaroxaban 10 MG Oral Tablet [Xarelto]
- Where
- Pakistan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi
Anemia, Venous Thrombosis
Utilization of TEG to Monitor Rivaroxaban Activity
The invesigators seek to devise a strategy for the assessment of Rivaroxaban activity in trauma and Emergency General Surgery (EGS) patients available as point-of-care testing.
- Trial name
- NCT02651909
- Testing
- blood sampling
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Matthew Neal MD
Atrial Fibrillation, Stroke Prevention in Patients With Atrial Fibrillation
CLOT-LESS - CLOsure Tailored: LEss Antithrombotic Strategy After LAAC for Stroke Prevention
This is a prospective, non-randomized, observational cohort study conducted at the FSBI "NMRC TPM" of the Ministry of Healthcare of the Russian Federation.
- Conditions
- Atrial Fibrillation, Stroke Prevention in Patients With Atrial Fibrillation, Left Atrial Appendage Closure, Hemorrhage
- Trial name
- CLOT-LESS (NCT07575867)
- Testing
- Left Atrial Appendage Closure, Apixaban 2.5 mg BID, Standard-dose DOAC
- Where
- Russia
- Volunteers
- 464 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Atrial Fibrillation
Efficacy and Safety of Different Doses of Rivaroxaban in Elderly Chinese Patients With Nonvalvular Atrial Fibrillation
From January 2023 to December 2025, 300 elderly patients with nonvalvular atrial fibrillation in Drum Tower Hospital Affiliated to Medical Scholl of Nanjing University will be enrolled to compare the efficacy and safety of…
- Trial name
- ESDDRECPNAF (NCT05638100)
- Volunteers
- 300 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Cancer, Venous Thromboembolism
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients.
- Conditions
- Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)
- Trial name
- CANVAS (NCT02744092)
- Testing
- Rivaroxaban, Apixaban, Edoxaban
- Where
- 151 sites in United States
- Volunteers
- 811 people
- Sponsor
- Alliance Foundation Trials, LLC.
Atrial Fibrillation, Myocardial Infarction
Triple or Dual Antithrombotic Therapy After PCI (TRIDUAL-PCI) Coronary Intervention in Patients With Non-valvular Atrial Fibrillation. Real-world Italian Multicenter Registry (TRIDUAL-PCI)
Aim of this study is to describe clinical and procedural characteristics of real-world population initiated on triple antithrombotic therapy (double antiplatelet therapy+anticoagulant) or double antithrombotic therapy (single…
- Conditions
- Atrial Fibrillation, Myocardial Infarction, Anticoagulant-induced Bleeding, Coronary Disease
- Trial name
- TRIDUAL-PCI (NCT04291287)
- Testing
- Antithrombotic Agent
- Where
- Italy
- Volunteers
- 1,500 people
- Sponsor
- Scientific Institute San Raffaele
Stroke, Acute, Atrial Fibrillation
OPTIMAS: OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke : a Randomised Controlled Trial
OPTIMAS is a large, prospective, partially blinded randomised controlled trial of early (within ≤4 days [96hrs]) or standard (between day 7 and day 14 after stroke onset) initiation of anticoagulation after stroke in patients…
- Trial name
- OPTIMAS (NCT03759938)
- Testing
- Direct oral anticoagulant (DOAC)
- Where
- 44 sites in United Kingdom
- Volunteers
- 3,648 people
- Sponsor
- University College, London
Acute Coronary Syndrome
To Assess the Efficacy and Safety of Dual Anticoagulants i.e. Rivaroxaban Plus Aspirin and Clopidogrel Plus Aspirin in Patients Suffering From an Acute Coronary Syndrome
Direct-acting oral anticoagulants (DOACs) have provided benefits to patients requiring anticoagulation for certain diseases by decreasing the burden of subcutaneous injections and the requirement for frequent monitoring through…
- Trial name
- ACCP (NCT05573958)
- Testing
- Rivaroxaban 2.5 Mg Oral Tablet, Clopidogrel tablet, Aspirin tablet
- Volunteers
- 90 people
- Sponsor
- Sarmad Zahoor
Atrial Fibrillation
Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists
The aim of this study is to assess the real world comparative effectiveness of Rivaroxaban prescribed in non-valvular atrial fibrillation (NVAF) routine care patients in Germany.
- Trial name
- NCT02960880
- Testing
- Rivaroxaban (Xarelto, BAY597939), Phenprocoumon (branded and generics)
- Where
- Germany
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Spinal Cord Injuries, Thromboembolism
Absorption of Rivaroxaban in Patients With Cervical Spinal Cord Injury
The primary objective of this study is to investigate the pharmacokinetic and -dynamic properties of rivaroxaban after oral administration in cervical spinal cord injury (SCI) individuals.
- Trial name
- rivaroxaban (NCT02970773)
- Testing
- Rivaroxaban Oral Tablet
- Where
- Switzerland
- Volunteers
- healthy volunteers welcome
- Sponsor
- Swiss Paraplegic Research, Nottwil
Nonvalvular Atrial Fibrillation
Evaluation of Hospital Readmissions Among Hospitalized Non-valvular Atrial Fibrillation (NVAF) Patients in the US
The overall objective of this proposal is to execute a real-world database analysis to evaluate hospital readmissions among hospitalized nonvalvular atrial fibrillation (NVAF) patients in the U.S Primary objective: To determine…
- Trial name
- NCT02674594
- Volunteers
- 30,000 people
- Sponsor
- Bristol-Myers Squibb
Coagulation
Clinical Performance Evaluation of Native Whole Blood Samples of Patients on DOACs With the Perosphere ClotChek™
The Perosphere ClotChek™ system consists of a hand-held, battery-operated blood coagulation instrument and disposable test cuvettes for use at the point-of-care (POC).
- Trial name
- NCT07012291
- Testing
- Whole Blood Clotting Time
- Where
- 4 sites in United States
- Volunteers
- 150 people
- Sponsor
- Perosphere Technologies Inc.
Glioma, Malignant
Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients
Glioma is a common brain tumor with a high risk of venous thromboembolism during treatment, especially in the months after surgery.
- Trial name
- NCT06196918
- Testing
- Rivaroxaban 10 MG
- Where
- 8 sites in China
- Volunteers
- 320 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Pharmacokinetics, Bioavailability
Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants
The primary objective of this study is to learn about the relative bioavailability (the extent to which the drug becomes available to the body) and pharmacokinetics (blood levels) of rivaroxaban in healthy participants after…
- Conditions
- Pharmacokinetics, Bioavailability, Healthy Participants
- Trial name
- NCT01464450
- Testing
- Rivaroxaban
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Janssen Scientific Affairs, LLC
Hematoma
Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events
The purpose of this study is to determine the best strategy to manage novel oral anti-coagulants (NOACs) at the time of pacemaker or defibrillator surgery.
- Trial name
- BRUISECONTROL2 (NCT01675076)
- Testing
- Dabigatran, Rivaroxaban, Apixaban
- Where
- 15 sites in Canada, Israel
- Volunteers
- 663 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Healthy
A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants
The purpose of this study is to assess the independent effects of both a 4-Factor prothrombin complex concentrate (PCC) - (Kcentra) and Tranexamic acid (TXA) on the bleeding parameters (bleeding duration and blood volume)…
- Trial name
- NCT02561923
- Testing
- Rivaroxaban, Tranexamic acid, Kcentra, a 4-factor PCC
- Where
- United States
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Janssen Scientific Affairs, LLC